AU2016307969C1 - Antibacterial agents comprising a pyrazino[2,3-b][1,4]oxazin-3-one or a related ring system - Google Patents

Antibacterial agents comprising a pyrazino[2,3-b][1,4]oxazin-3-one or a related ring system Download PDF

Info

Publication number
AU2016307969C1
AU2016307969C1 AU2016307969A AU2016307969A AU2016307969C1 AU 2016307969 C1 AU2016307969 C1 AU 2016307969C1 AU 2016307969 A AU2016307969 A AU 2016307969A AU 2016307969 A AU2016307969 A AU 2016307969A AU 2016307969 C1 AU2016307969 C1 AU 2016307969C1
Authority
AU
Australia
Prior art keywords
methyl
amino
pyrazino
compound
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016307969A
Other languages
English (en)
Other versions
AU2016307969B2 (en
AU2016307969A1 (en
Inventor
Haifeng Cui
Alan Hennessy
Qi Jin
Timothy James Miles
Stephen Frederick Moss
Neil David Pearson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of AU2016307969A1 publication Critical patent/AU2016307969A1/en
Priority to AU2019200226A priority Critical patent/AU2019200226B2/en
Application granted granted Critical
Publication of AU2016307969B2 publication Critical patent/AU2016307969B2/en
Publication of AU2016307969C1 publication Critical patent/AU2016307969C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
AU2016307969A 2015-08-16 2016-08-15 Antibacterial agents comprising a pyrazino[2,3-b][1,4]oxazin-3-one or a related ring system Ceased AU2016307969C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019200226A AU2019200226B2 (en) 2015-08-16 2019-01-14 Antibacterial agents comprising a pyrazino[2,3-b][1,4]oxazin-3-one or a related ring system

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562205732P 2015-08-16 2015-08-16
US62/205,732 2015-08-16
US201662308928P 2016-03-16 2016-03-16
US62/308,928 2016-03-16
PCT/IB2016/054890 WO2017029602A2 (en) 2015-08-16 2016-08-15 Compounds for use in antibacterial applications

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019200226A Division AU2019200226B2 (en) 2015-08-16 2019-01-14 Antibacterial agents comprising a pyrazino[2,3-b][1,4]oxazin-3-one or a related ring system

Publications (3)

Publication Number Publication Date
AU2016307969A1 AU2016307969A1 (en) 2018-03-08
AU2016307969B2 AU2016307969B2 (en) 2019-02-14
AU2016307969C1 true AU2016307969C1 (en) 2019-09-05

Family

ID=57218948

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016307969A Ceased AU2016307969C1 (en) 2015-08-16 2016-08-15 Antibacterial agents comprising a pyrazino[2,3-b][1,4]oxazin-3-one or a related ring system
AU2019200226A Ceased AU2019200226B2 (en) 2015-08-16 2019-01-14 Antibacterial agents comprising a pyrazino[2,3-b][1,4]oxazin-3-one or a related ring system

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019200226A Ceased AU2019200226B2 (en) 2015-08-16 2019-01-14 Antibacterial agents comprising a pyrazino[2,3-b][1,4]oxazin-3-one or a related ring system

Country Status (22)

Country Link
US (2) US10364254B2 (https=)
EP (1) EP3334739A2 (https=)
JP (1) JP6757402B2 (https=)
KR (1) KR20180038046A (https=)
CN (1) CN108137616B (https=)
AU (2) AU2016307969C1 (https=)
CA (1) CA2995715A1 (https=)
CL (1) CL2018000403A1 (https=)
CO (1) CO2018002204A2 (https=)
CR (1) CR20180111A (https=)
DO (1) DOP2018000049A (https=)
EA (1) EA033314B1 (https=)
HK (1) HK1248680A1 (https=)
IL (1) IL257265B (https=)
MA (1) MA42621A (https=)
MX (1) MX2018002033A (https=)
PE (1) PE20181143A1 (https=)
PH (1) PH12018500358A1 (https=)
TW (1) TW201722965A (https=)
UY (1) UY36851A (https=)
WO (1) WO2017029602A2 (https=)
ZA (1) ZA201800722B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36851A (es) * 2015-08-16 2017-03-31 Glaxosmithkline Ip Dev Ltd Compuestos para uso en aplicaciones antibacterianas
WO2019180634A1 (en) 2018-03-23 2019-09-26 Glaxosmithkline Intellectual Property Development Limited Synthesis of oxazinone-containing bicyclic aromatic and heteroaromatic aldehydes
WO2021009212A1 (en) 2019-07-16 2021-01-21 Idorsia Pharmaceuticals Ltd Antibacterial quinolone derivatives
CN111269247B (zh) * 2020-03-04 2020-11-24 河南科技大学第一附属医院 具有抑制大肠杆菌作用的噻嗪酮药物分子的制备方法
KR20240161147A (ko) 2022-03-14 2024-11-12 슬랩 파마슈티컬스 엘엘씨 다중 사이클릭 화합물
TW202542149A (zh) 2023-12-21 2025-11-01 英商葛蘭素史密斯克藍智慧財產權有限公司 化合物及其用途

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4632671B1 (https=) * 1969-10-13 1971-09-23 Eisai Co Ltd
WO2004002992A1 (en) * 2002-06-26 2004-01-08 Glaxo Group Limited Compounds
WO2004002490A2 (en) * 2002-06-26 2004-01-08 Glaxo Group Limited Piperidine compounds as antibacterials
WO2004087145A2 (en) * 2003-03-27 2004-10-14 Glaxo Group Limited Antibacterial agents
WO2006081264A1 (en) * 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
WO2007093963A1 (en) * 2006-02-15 2007-08-23 Actelion Pharmaceuticals Ltd Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives
WO2008078305A2 (en) * 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd 4-(1-amino-ethyl)-cyclohexylamine derivatives
WO2008128961A1 (en) * 2007-04-20 2008-10-30 Glaxo Group Limited Compounds
US20090131444A1 (en) * 2005-05-24 2009-05-21 Astrazeneca Ab Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity
US20090270374A1 (en) * 2006-07-20 2009-10-29 Llius Ballell Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
WO2010046388A1 (en) * 2008-10-23 2010-04-29 Glaxo Group Limited Substituted (aza) -1-methyl-1h-quinolin-2-ones as antibacterials
WO2010055348A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab [4- (1-amino-ethyl) -cyclohexyl] -methyl-amines as antibacterials
WO2011148962A1 (ja) * 2010-05-25 2011-12-01 大正製薬株式会社 新規な複素環化合物又はその塩
US20140243302A1 (en) * 2011-06-27 2014-08-28 Merck Sharp & Dohme Corporation Bridged bicyclic compounds for the treatment of bacterial infections

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
DK172541B1 (da) 1982-10-08 1998-12-07 Glaxo Group Ltd Apparat til administrering af medikamenter til patienter og en medikamentpakning til brug i apparatet
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
DE3682457D1 (de) 1985-07-30 1991-12-19 Glaxo Group Ltd Geraet zur verabreichung von medikamenten an patienten.
JPH0733379B2 (ja) * 1986-06-27 1995-04-12 エーザイ株式会社 光学活性α−トコフエロ−ルの製造方法
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SK280968B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Balenie medikamentu na použite v inhalačnom prístroji
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
FR2798656B1 (fr) 1999-09-17 2004-12-17 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent
DE60025048D1 (de) 2000-07-21 2006-01-26 Ljudmila Petrovna Maljuk Teller für stehempfänge
CZ2003243A3 (cs) 2000-07-26 2003-09-17 Smithkline Beecham P. L. C. Aminopiperidinové chinoliny a jejich azaisosterické analogy s antibakteriální aktivitou
FR2816618B1 (fr) 2000-11-15 2002-12-27 Aventis Pharma Sa Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
EP1345903A1 (en) 2000-12-21 2003-09-24 Ciba SC Holding AG Crystalline forms of cerivastatin sodium
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
EP1470125A1 (en) 2002-01-29 2004-10-27 Glaxo Group Limited Aminopiperidine derivatives
WO2003064431A2 (en) 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
US20060014786A1 (en) * 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
DE60313173T2 (de) 2002-06-27 2008-01-03 F. Hoffmann-La Roche Ag Synthese von purin-derivaten
GB0217294D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
FR2844268B1 (fr) 2002-09-11 2004-10-22 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent
FR2844270B1 (fr) 2002-09-11 2006-05-19 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent
WO2004035569A2 (de) 2002-10-10 2004-04-29 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue verbindungen mit antibakterieller aktivität
ATE479683T1 (de) 2002-11-05 2010-09-15 Glaxo Group Ltd Antibakterielle mittel
DE60331849D1 (de) 2002-11-05 2010-05-06 Glaxosmithkline Llc Antibakterielle wirkstoffe
TW200427688A (en) 2002-12-18 2004-12-16 Glaxo Group Ltd Antibacterial agents
FR2852954B1 (fr) 2003-03-28 2006-07-14 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
DE10316081A1 (de) 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
FR2858619B1 (fr) 2003-08-08 2006-12-22 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
US9214590B2 (en) 2003-12-19 2015-12-15 The University Of North Carolina At Chapel Hill High fidelity nano-structures and arrays for photovoltaics and methods of making the same
DK1704585T3 (en) 2003-12-19 2017-05-22 Univ North Carolina Chapel Hill Methods for preparing isolated micro- and nanostructures using soft lithography or printing lithography
FR2867472B1 (fr) 2004-03-12 2008-07-18 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
US7691850B2 (en) 2004-06-15 2010-04-06 Glaxo Group Limited Antibacterial agents
FR2872164B1 (fr) 2004-06-29 2006-11-17 Aventis Pharma Sa Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
US20070254872A1 (en) 2004-07-08 2007-11-01 Glaxo Group Limited Antibacterial Agents
US20080194547A1 (en) 2004-07-09 2008-08-14 Glaxo Group Limited Antibacterial Agents
US7648984B2 (en) 2004-07-13 2010-01-19 Glaxo Group Limited Antibacterial agents
US20070270417A1 (en) 2004-07-22 2007-11-22 Glaxo Group Limited Antibacterial Agents
US7655648B2 (en) 2004-08-02 2010-02-02 Glaxo Group Limited Antibacterial agents
US20070161627A1 (en) 2004-08-09 2007-07-12 Miller William H Antibacterial agents
DE102004041163A1 (de) * 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
CA2580621A1 (en) 2004-09-24 2006-03-30 Actelion Pharmaceuticals Ltd New bicyclic antibiotics
WO2006038172A1 (en) 2004-10-05 2006-04-13 Actelion Pharmaceuticals Ltd New piperidine antibiotics
JP5314244B2 (ja) 2004-10-27 2013-10-16 富山化学工業株式会社 新規な含窒素複素環化合物およびその塩
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
WO2006137485A1 (ja) 2005-06-24 2006-12-28 Toyama Chemical Co., Ltd. 新規な含窒素複素環化合物およびその塩
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
EP1922364A4 (en) 2005-08-09 2010-04-21 Univ North Carolina METHOD AND MATERIALS FOR PRODUCING MICROFLUIDIC DEVICES
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
WO2007081876A2 (en) 2006-01-04 2007-07-19 Liquidia Technologies, Inc. Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
CN101454319B (zh) 2006-05-26 2012-06-27 富山化学工业株式会社 新杂环化合物或其盐及其中间体
US8465775B2 (en) 2006-07-27 2013-06-18 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells
US8128393B2 (en) 2006-12-04 2012-03-06 Liquidia Technologies, Inc. Methods and materials for fabricating laminate nanomolds and nanoparticles therefrom
WO2009024342A2 (en) * 2007-08-23 2009-02-26 Syngenta Participations Ag Novel microbiocides
CN103660089B (zh) 2007-10-12 2017-04-12 流体科技公司 用于生产颗粒和图案化膜的系统和方法
JP5620636B2 (ja) 2007-11-26 2014-11-05 富山化学工業株式会社 新規な複素環化合物またはその塩を含有する抗菌剤
BRPI0920895A8 (pt) * 2008-10-07 2017-12-26 Actelion Pharmaceuticals Ltd Compostos antibióticos de oxazolidinona tricíclica
US8444907B2 (en) 2008-12-05 2013-05-21 Liquidia Technologies, Inc. Method for producing patterned materials
CN102232078B (zh) * 2008-12-12 2014-07-16 埃科特莱茵药品有限公司 5-氨基-2-(1-羟基-乙基)-四氢吡喃衍生物
US20120114554A1 (en) 2009-07-13 2012-05-10 Liquidia Technologies, Inc. Engineered Aerosol Particles, And Associated Methods
CA2854266A1 (en) * 2011-11-30 2013-06-06 Actelion Pharmaceuticals Ltd 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics
PL2986607T3 (pl) 2013-04-16 2017-11-30 Idorsia Pharmaceuticals Ltd Przeciwbakteryjne pochodne biaromatyczne
UY36851A (es) * 2015-08-16 2017-03-31 Glaxosmithkline Ip Dev Ltd Compuestos para uso en aplicaciones antibacterianas

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4632671B1 (https=) * 1969-10-13 1971-09-23 Eisai Co Ltd
WO2004002992A1 (en) * 2002-06-26 2004-01-08 Glaxo Group Limited Compounds
WO2004002490A2 (en) * 2002-06-26 2004-01-08 Glaxo Group Limited Piperidine compounds as antibacterials
WO2004087145A2 (en) * 2003-03-27 2004-10-14 Glaxo Group Limited Antibacterial agents
WO2006081264A1 (en) * 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
US20090131444A1 (en) * 2005-05-24 2009-05-21 Astrazeneca Ab Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity
WO2007093963A1 (en) * 2006-02-15 2007-08-23 Actelion Pharmaceuticals Ltd Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives
US20090270374A1 (en) * 2006-07-20 2009-10-29 Llius Ballell Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
WO2008078305A2 (en) * 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd 4-(1-amino-ethyl)-cyclohexylamine derivatives
US20100029623A1 (en) * 2006-12-22 2010-02-04 Actelion Pharmaceuticals Ltd. 4-(1-amino-ethyl)-cyclohexylamine derivatives
WO2008128961A1 (en) * 2007-04-20 2008-10-30 Glaxo Group Limited Compounds
WO2010046388A1 (en) * 2008-10-23 2010-04-29 Glaxo Group Limited Substituted (aza) -1-methyl-1h-quinolin-2-ones as antibacterials
WO2010055348A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab [4- (1-amino-ethyl) -cyclohexyl] -methyl-amines as antibacterials
WO2011148962A1 (ja) * 2010-05-25 2011-12-01 大正製薬株式会社 新規な複素環化合物又はその塩
US20140243302A1 (en) * 2011-06-27 2014-08-28 Merck Sharp & Dohme Corporation Bridged bicyclic compounds for the treatment of bacterial infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RECK FOLKERT ET AL, "Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs)", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, (2014-08-04), vol. 22, no. 19, pages 5392 - 5409 *

Also Published As

Publication number Publication date
EP3334739A2 (en) 2018-06-20
KR20180038046A (ko) 2018-04-13
US10683307B2 (en) 2020-06-16
US20190031680A1 (en) 2019-01-31
EA201890412A1 (ru) 2018-08-31
WO2017029602A2 (en) 2017-02-23
CN108137616A (zh) 2018-06-08
AU2019200226A1 (en) 2019-01-31
HK1248680A1 (zh) 2018-10-19
AU2019200226B2 (en) 2020-01-23
CN108137616B (zh) 2020-06-26
DOP2018000049A (es) 2018-03-30
US20190270755A1 (en) 2019-09-05
IL257265A (en) 2018-03-29
CR20180111A (es) 2018-04-12
WO2017029602A3 (en) 2017-04-13
UY36851A (es) 2017-03-31
MX2018002033A (es) 2018-06-15
PE20181143A1 (es) 2018-07-17
CO2018002204A2 (es) 2018-06-20
JP6757402B2 (ja) 2020-09-16
CL2018000403A1 (es) 2018-07-06
AU2016307969B2 (en) 2019-02-14
EA033314B1 (ru) 2019-09-30
MA42621A (fr) 2018-06-20
AU2016307969A1 (en) 2018-03-08
JP2018523675A (ja) 2018-08-23
PH12018500358A1 (en) 2018-09-03
TW201722965A (zh) 2017-07-01
CA2995715A1 (en) 2017-02-23
ZA201800722B (en) 2019-07-31
US10364254B2 (en) 2019-07-30
IL257265B (en) 2020-07-30

Similar Documents

Publication Publication Date Title
AU2019200226B2 (en) Antibacterial agents comprising a pyrazino[2,3-b][1,4]oxazin-3-one or a related ring system
CN115087440A (zh) Trpml调节剂
UA128751C2 (uk) Інгібітори rip1k
JP2023134444A (ja) ピペリジニル－３－（アリールオキシ）プロパンアミド及びプロパノエート
JP2010521528A (ja) Ｃｎｓ活性化合物としてのインドリジン及びそのアザ類似誘導体
CA2876370A1 (en) Compounds and methods for treating hiv
CA2959747C (en) Compounds as crth2 antagonist and uses thereof
WO2016015593A1 (en) FACTOR XIa INHIBITORS
AU2016209623B2 (en) Factor XIa inhibitors
BRPI0808378A2 (pt) Composto de 6-benzil-2,3,4,7-treta-hidro-indolo[2,3-c] quinolina úteis como inibidores de pde5
CN103396396B (zh) 胺基烷酰克林沙星及其应用
WO2023109909A1 (zh) 一种芳杂环类化合物及其制备方法和用途
JP2008528604A (ja) 抗菌剤
JP6526064B2 (ja) ピリドピリミジンジオン誘導体
WO2017093938A1 (en) Tetrahydroisoquinoline derivatives
CN103450220B (zh) 一种硝基咪唑类化合物及其在药学中的用途
HK40112157A (zh) Enpp1抑制剂的药物用途
JPH04159283A (ja) リファマイシン誘導体およびその製造方法
WO2025214463A1 (zh) 含有三并环结构的化合物
TW202535889A (zh) 泛-kras抑制劑及其在醫藥上的應用
WO2025230875A1 (en) Compounds and their use for treatment of hemoglobinopathies
WO2022234287A1 (en) Imidazopyridazine derivatives useful as trk inhibitors
JPH05117280A (ja) アミノ酸置換チアゼトキノリン−３−カルボン酸誘導体
HK40000285A (en) Amino pyrimidine compounds useful as ssao inhibitors

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 MAY 2019

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 MAY 2019

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired